Biotron Limited (BIT) is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and a promising preclinical program for HBV. The technology targets viroporin proteins which enables the pathogenicity of several viruses including hepatitis C, HIV-1, Dengue, Zika viruses.
Biotron Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.biotron.com.au.
This a small cap company with market cap of 53 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how bit dividend grows in the recent years.